New hope for rare thymus cancer: targeted drug enters phase 2 trial
NCT ID NCT07343453
First seen Jan 17, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study tests a drug called sacituzumab tirumotecan in 38 people with advanced thymic epithelial tumors that have worsened after at least one prior therapy. The drug is an antibody-drug conjugate that targets a protein called TROP2 on tumor cells. The main goal is to see how many patients' tumors shrink or disappear. This is a single-arm, phase 2 trial, meaning all participants receive the same treatment and there is no placebo group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC EPITHELIAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.